At the same time, in vivo experiments for deletion or overexpression of PPARγ exhibited its prosteatotic role in the development of NAFLD or NASH.103, 104, 105 PPARγ also regulates lipid deposition in liver and other tissues.106 Utilizing the positive effects of PPARγ while limiting its negative effects by targeting other PPARs has paved the way for the development of a new batch of dual and pan agonists. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.